Turn Therapeutics Enters Into Global Supply, Development, And License Agreement With Medline
Benzinga Newsdesk 1 year ago
News
Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, today announced it has entered into a global
Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology, wound, and anti-infective therapies, today announced it has entered into a global supply, development, and license agreement with Medline, the largest provider of medical-surgical products and supply chain solutions serving all points of care.
The agreement establishes a long-term collaboration to develop, manufacture, and commercialize products leveraging Turn's proprietary PermaFusion® delivery platform.